{
    "Trade/Device Name(s)": [
        "VITEK\u00ae 2 AST Gram-Positive Telavancin",
        "VITEK\u00ae 2 AST-GP Telavancin"
    ],
    "Submitter Information": "bioM\u00e9rieux, Inc.",
    "510(k) Number": "K212243",
    "Predicate Device Reference 510(k) Number(s)": [
        "K190616"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "LON",
        "LTT",
        "LTW"
    ],
    "Summary Letter Date": "July 14, 2021",
    "Summary Letter Received Date": "July 19, 2021",
    "Submission Date": "July 14, 2021",
    "Regulation Number(s)": [
        "21 CFR 866.1645"
    ],
    "Regulation Name(s)": [
        "Fully Automated Short-Term Incubation Cycle Antimicrobial Susceptibility System"
    ],
    "Analyte Class(es)": [
        "microbiology"
    ],
    "Analyte(s)": [
        "Telavancin"
    ],
    "Specimen Type(s)": [
        "Gram positive microorganisms"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "VITEK\u00ae 2 System",
        "VITEK\u00ae 2 Compact System"
    ],
    "Method(s)/Technology(ies)": [
        "Automated microdilution minimum inhibitory concentration (MIC) assay"
    ],
    "Methodologies": [
        "Microdilution",
        "Automated susceptibility testing",
        "Growth pattern analysis"
    ],
    "Submission Type(s)": [
        "Assay",
        "Test Card"
    ],
    "Document Summary": "FDA 510(k) summary for VITEK\u00ae 2 AST Gram-Positive Telavancin automated antimicrobial susceptibility test card for Gram positive bacteria",
    "Indications for Use Summary": "For in vitro antimicrobial susceptibility testing of Gram positive microorganisms using VITEK\u00ae 2 and VITEK\u00ae 2 Compact Systems, aiding determination of susceptibility to Telavancin including Staphylococcus aureus and Enterococcus faecalis (vancomycin-susceptible isolates only)",
    "fda_folder": "Microbiology"
}